RecruitingNCT07508319
Role of the Immune System in Preventing Laryngeal Cancer
Laryngeal Dysplasia and Progression to Carcinoma: Investigating Genetic and Immune Alterations Predictive of Malignant Transformation
Sponsor
European Institute of Oncology
Enrollment
3 participants
Start Date
Nov 19, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with head & neck cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07508319
Related Trials
Feasibility Study on the Implementation of a Supervised, Home-based Adapted Physical Activity Program for Patients With Head and Neck Cancer
NCT075603971 location
Improving Dental Care for Patients With Head and Neck Tumors
NCT073283471 location
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
NCT0767223611 locations
SL-28 for Advanced Solid Tumours
NCT073417371 location
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT076017371 location